Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Weight loss drugs stories

Nov 16, 2026

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00
Nov 14, 2026

Eli Lilly releases new obesity drug clinical trial data at ObesityWeek

Eli Lilly released new clinical trial data for its obesity drugs at the ObesityWeek 2026 medical conference, showing weight loss benefits, though full results have not yet been published.

Nov 14, 2026·2 sources
00
Nov 11, 2026

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 2026·3 sources
00
Nov 4, 2026

AstraZeneca made $10 billion offer for obesity drugmaker Rhythm Pharmaceuticals

AstraZeneca made a $10 billion takeover offer for Rhythm Pharmaceuticals, which specializes in treatments for metabolic conditions and severe obesity, according to sources familiar with the matter.

Nov 4, 2026·2 sources
00
Oct 29, 2026

Eli Lilly raises revenue forecast on weight-loss drug demand

Eli Lilly raised its full-year revenue forecast by $5 billion and beat third-quarter profit estimates driven by booming demand for its injectable weight-loss drugs, particularly among older Americans.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources
00
Oct 26, 2026

Eli Lilly wins court ruling allowing weight-loss drug ads against Novo Nordisk

A US court denied Novo Nordisk's request to temporarily block Eli Lilly from using advertisements claiming its obesity drugs are more powerful, a setback for Novo as it battles to regain market share.

Oct 26, 2026·2 sources
00
Oct 16, 2026

Eli Lilly's weight-loss pill Foundayo wins EU regulatory backing

The European Medicines Agency's committee recommended approval of Eli Lilly's oral weight-loss drug Foundayo for obesity and diabetes, following Novo Nordisk's Wegovy as the second oral obesity drug to win the agency's backing.

Oct 16, 2026·2 sources
00
Oct 1, 2026

Survodutide shows modest weight loss in phase 3 diabetes trial, trailing competitors

Boehringer Ingelheim's investigational dual GIP/GLP-1 agonist survodutide achieved up to 9.8% weight loss in the phase 3 SYNCHRONIZE-2 trial for adults with type 2 diabetes and obesity, meeting primary endpoints but falling short of competing drugs. The results raised tolerability concerns and led to a drop in partner Zealand Pharma's stock.

Oct 1, 2026·6 sources
00
Sep 20, 2026

Novo Nordisk cuts 13,000 jobs as CEO outlines strategy beyond weight-loss drugs

Novo Nordisk announced it cut 13,000 jobs in the past year and outlined plans to diversify beyond obesity drugs with new pipeline assets and bolt-on acquisitions. CEO Mike Doustdar faced investor skepticism about pricing power and strategy ahead of patent expiries.

Sep 20, 2026·9 sources
00
Aug 25, 2026

US employers increasingly dropping weight-loss drug coverage as healthcare costs rise nearly 10%

About 14% of US employers plan to drop GLP-1 drug coverage in 2027 as healthcare costs are projected to increase by nearly 10%, according to surveys from the Business Group on Health and Aon.

Aug 25, 2026·2 sources
00
Aug 12, 2026

Eli Lilly escalates legal fight against black market for experimental weight-loss drug retatrutide

Eli Lilly is stepping up legal action against a booming black market for retatrutide, an experimental weight-loss drug the company is counting on to expand its franchise beyond approved medications like Zepbound.

Aug 12, 2026·2 sources
00
Jun 8, 2026

Zealand Pharma Shares Plunge 25% After Safety Data Raises Concerns Over Experimental Weight Loss Drug

Shares of Danish drugmaker Zealand Pharma dropped as much as 26% after new safety data on its experimental obesity medicine raised investor concerns over potential side effects.

Jun 8, 2026·1 source
00

Top claims

  • ▪Almost 80 percent of children aged 6 to under 12 given Wegovy in Novo Nordisk's trial reduced their body mass index by at least 10 percent over 68 weeks
  • ▪In the 68-week trial, 40 percent of children aged 6 to under 12 taking Wegovy were no longer classified as having obesity, compared with none in the placebo group
  • ▪As of November 16, 2026, Novo Nordisk has not announced if or when it will file for regulatory approval to treat children under 12 with Wegovy

Subtopics

Eli Lilly8Clinical trials6Novo Nordisk6Obesity treatment6Zepbound6GLP-13Pharma3Retatrutide3Weight management3Blood sugar & insulin2Corporate strategy2Drug development2Drug Policy, Pricing & Approval2GLP-1 medications2GLP-1 receptor agonists2Mergers and acquisitions2Pharmaceutical Industry2Adolescent health1Childhood obesity1Drug pricing1Drug safety1Foundao1GLP-1 / Weight-Loss Medications1GLP-1 agonists1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories